Baxter SG&A Expenses 2010-2024 | BAX

Baxter sg&a expenses for the twelve months ending June 30, 2024 were $4.035B, a 6.3% increase year-over-year.

  • Baxter annual sg&a expenses for 2023 were $3.946B, a 2.25% increase from 2022.
  • Baxter annual sg&a expenses for 2022 were $3.859B, a 35.64% increase from 2021.
  • Baxter annual sg&a expenses for 2021 were $2.845B, a 15.23% increase from 2020.

Baxter SG&A Expenses 2010-2024 | BAX

  • Baxter annual sg&a expenses for 2023 were $3.946B, a 2.25% increase from 2022.
  • Baxter annual sg&a expenses for 2022 were $3.859B, a 35.64% increase from 2021.
  • Baxter annual sg&a expenses for 2021 were $2.845B, a 15.23% increase from 2020.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$199.9B
Stryker (SYK)$137.7B
Boston Scientific (BSX)$121.6B
Medtronic (MDT)$113B
EssilorLuxottica (ESLOY)$104.4B
Haleon (HLN)$48.1B
Lonza Group Ag (LZAGY)$45.4B
ResMed (RMD)$35B
Koninklijke Philips (PHG)$29B
Terumo (TRUMY)$27.9B
Zimmer Biomet Holdings (ZBH)$21.6B
Insulet (PODD)$16.6B
Smith & Nephew SNATS (SNN)$13.4B
Bio-Rad Laboratories (BIO)$9.5B
Demant (WILYY)$9.2B
BellRing Brands (BRBR)$7.7B
Lantheus Holdings (LNTH)$7.5B
ICU Medical (ICUI)$4.3B
TG Therapeutics (TGTX)$3.9B
Haemonetics (HAE)$3.9B
Perrigo (PRGO)$3.8B
GN Store Nord (GNNDY)$3.8B
Neogen (NEOG)$3.7B
Prestige Consumer Healthcare (PBH)$3.6B
Envista Holdings (NVST)$3.3B
QuidelOrtho (QDEL)$3.1B
Agios Pharmaceuticals (AGIO)$2.6B
Maravai LifeSciences Holdings (MRVI)$2.3B
Green Thumb Industries (GTBIF)$2.2B
LeMaitre Vascular (LMAT)$2B